ArticleMedical oncology (Northwood, London, England)2016
The novel miR-9501 inhibits cell proliferation, migration and activates apoptosis in non-small cell lung cancer.
Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MIR-379-5p Expression in Endometrial Cancer and Its Correlation with ROR1 Expression.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- miR-455-5p promotes cell growth and invasion by targeting SOCO3 in non-small cell lung cancer.Oncotarget · 2017Article
- Article
- HOXD-AS1 functions as an oncogenic ceRNA to promote NSCLC cell progression by sequestering miR-147a.OncoTargets and therapy · 2017Article
- MicroRNA-211 promotes non-small-cell lung cancer proliferation and invasion by targeting MxA.OncoTargets and therapy · 2017Article
- MicroRNA-641 inhibits lung cancer cells proliferation, metastasis but promotes apoptosis in cells by targeting PDCD4.International journal of clinical and experimental pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidences suggest that lots of microRNAs (miRNAs) play crucial roles in (patho-)physiological processes of lung cancer, including metastasis, drug-resistance or tumorigenesis. They mediate the progression of cell growth, migration and invasion by regulating the expression of special genes. MiRNA expression patterns could also serve as diagnostic/prognostic biomarkers. Cancer therapies mediated by miRNAs remain tremendous potential and challenges. Our previous small RNA-seq assay found that the novel miR-9501 was down-regulated in lung cancer tissues compared with adjacent non-cancer tissues. In this study, our results verified that miR-9501 was significantly down-regulated in lung cancer tissues and its expression levels were remarkably suppressed in non-small cell lung cancer cell lines. Then, we characterized and investigated the novel miR-9501 in A549 cells. Transient transfection of miR-9501 into cultured A549 cells led to remarkable decrease in cell proliferation, migration and increase apoptosis. These data demonstrated that miR-9501 might be a tumor suppressor for lung cancer therapy.
Indexed as
Identifiers
27734264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.